Canadian Industry Reaches Fresh Pricing Agreement
New Three-Year CGPA-pCPA Deal Replaces Previous National Pricing Framework
The Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance have agreed a new three-year national pricing initiative for generic medicines.
You may also be interested in...
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.
A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.
Prices of nearly 70 commonly-prescribed generics in Canada will see their prices cut by between 25% and 40% from 1 April 2018, under a new five-year initiative that has been agreed between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) for participating federal, provincial and territorial public drug plans.